Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis

0
41

Strategy supports global need and has potential use in growing home healthcare market

New York, New York–(Newsfile Corp. – June 7, 2022) – PCG Digital — Rising to the challenge in 2022, late-stage biopharma company Soligenix (NASDAQ: SNGX) continues to move forward with developing and commercializing products to treat rare diseases where there is an unmet medical need.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/126632